NCT04606433View on ClinicalTrials.gov

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non Hodgkin LymphomaAcute Lymphoblastic Leukemia
Interventions
DRUG

GNC-038

Administration by intravenous infusion.

Trial Locations (10)

300000

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

Unknown

The Second Hospital of Anhui Medical University, Hefei

Peking University Third Hospital, Beijing

Chongqing University Cancer Hospital, Chongqing

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Guangdong Provincial People's Hospital, Guangzhou

Nanfang Hospital of Southern Medical University, Guangzhou

Xiangya Hospital Central South University, Changsha

Shanghai Tongji Hospital, Shanghai

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT04606433 - Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter